[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553882":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":93,"collaborators":7,"id":95,"slug":7,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":96,"sex":102,"minAge":103,"maxAge":7,"enrollmentInfo":104,"targetDuration":7,"studyType":107,"phases":7,"briefSummary":108,"conditions":109,"keywords":7,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[15,28,33,43,52,61,68,73,78,83,88],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":7},"Research Site","NOT_YET_RECRUITING","Belo Horizonte","Minas Gerais","30110-934","Brazil",{"type":23,"coordinates":24},"Point",[25,26],-43.93778,-19.92083,{"lat":26,"lon":25},{"facility":16,"status":17,"city":18,"state":19,"zip":29,"country":21,"cosmosGeoPoint":30,"geoPoint":32,"contacts":7},"30380-420",{"type":23,"coordinates":31},[25,26],{"lat":26,"lon":25},{"facility":16,"status":34,"city":35,"state":36,"zip":37,"country":21,"cosmosGeoPoint":38,"geoPoint":42,"contacts":7},"RECRUITING","Natal","Rio Grande do Norte","59062-000",{"type":23,"coordinates":39},[40,41],-35.20944,-5.795,{"lat":41,"lon":40},{"facility":16,"status":17,"city":44,"state":45,"zip":46,"country":21,"cosmosGeoPoint":47,"geoPoint":51,"contacts":7},"Porto Alegre","Rio Grande do Sul","90560-032",{"type":23,"coordinates":48},[49,50],-51.23019,-30.03283,{"lat":50,"lon":49},{"facility":16,"status":17,"city":53,"state":54,"zip":55,"country":21,"cosmosGeoPoint":56,"geoPoint":60,"contacts":7},"São José do Rio Preto","São Paulo","15090-000",{"type":23,"coordinates":57},[58,59],-49.37944,-20.81972,{"lat":59,"lon":58},{"facility":16,"status":34,"city":54,"state":7,"zip":62,"country":21,"cosmosGeoPoint":63,"geoPoint":67,"contacts":7},"01308-050",{"type":23,"coordinates":64},[65,66],-46.63611,-23.5475,{"lat":66,"lon":65},{"facility":16,"status":17,"city":54,"state":7,"zip":69,"country":21,"cosmosGeoPoint":70,"geoPoint":72,"contacts":7},"01323-001",{"type":23,"coordinates":71},[65,66],{"lat":66,"lon":65},{"facility":16,"status":34,"city":54,"state":7,"zip":74,"country":21,"cosmosGeoPoint":75,"geoPoint":77,"contacts":7},"01323-020",{"type":23,"coordinates":76},[65,66],{"lat":66,"lon":65},{"facility":16,"status":34,"city":54,"state":7,"zip":79,"country":21,"cosmosGeoPoint":80,"geoPoint":82,"contacts":7},"01333-010",{"type":23,"coordinates":81},[65,66],{"lat":66,"lon":65},{"facility":16,"status":17,"city":54,"state":7,"zip":84,"country":21,"cosmosGeoPoint":85,"geoPoint":87,"contacts":7},"01509-010",{"type":23,"coordinates":86},[65,66],{"lat":66,"lon":65},{"facility":16,"status":34,"city":54,"state":7,"zip":89,"country":21,"cosmosGeoPoint":90,"geoPoint":92,"contacts":7},"05652-900",{"type":23,"coordinates":91},[65,66],{"lat":66,"lon":65},{"type":94,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100553882",false,"NCT06491862","RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil","RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil","RACE-2L","Inclusion Criteria\n\n* Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB\u002FIIIC not eligible for curative-intent therapies or stage IV\u002FM1 (a\u002Fm NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2)\n* Aged at least 18 years at first diagnosis of a\u002Fm NSCLC\n* For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy.\n* For the non\\_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC)\n* Patient must have received at least line of therapy of an active agent after failing PTC.\n\nExclusion Criteria\n\n* Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts.\n* Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward.","ALL","18 Years",{"count":105,"type":106},250,"ESTIMATED","OBSERVATIONAL","The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a\u002Fm non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.",[110],"Non-squamous Non-Small Cell Lung Cancer","2026-06-19",{"date":113,"type":114},"2026-06-23","ACTUAL",{"date":116,"type":114},"2024-07-25",{"date":118,"type":106},"2026-06-30",{"name":5,"class":6},11]